Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

MLA

Routy, Bertrand, et al. “Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy against Epithelial Tumors.” Science (New York, N.Y.), vol. 359, no. 6371, Jan. 2018, pp. 91–97. EBSCOhost, https://doi.org/10.1126/science.aan3706.

APA

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., Fidelle, M., Flament, C., Poirier-Colame, V., Opolon, P., Klein, C., Iribarren, K., Mondragón, L., Jacquelot, N., Qu, B., … Zitvogel, L. (2018). Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science (New York, N.Y.), 359(6371), 91–97. https://doi.org/10.1126/science.aan3706

Chicago

Routy, Bertrand, Emmanuelle Le Chatelier, Lisa Derosa, Connie P M Duong, Maryam Tidjani Alou, Romain Daillère, Aurélie Fluckiger, et al. 2018. “Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy against Epithelial Tumors.” Science (New York, N.Y.) 359 (6371): 91–97. doi:10.1126/science.aan3706.